"Psychedelic therapy is highly effective for treatment resistant depression."
Evidence8
A 2022 randomized trial of 233 treatment-resistant patients found a 25 mg psilocybin session reduced a clinician-rated depression score by about 12 points at week 3 versus 5.4 points in the 1 mg control group.
This double-blind trial randomized 233 adults with treatment-resistant depression to a single 25 mg, 10 mg, or 1 mg dose with psychological support.
At week 3, the average Montgomery-Asberg depression score dropped by about 12.0 points in the 25 mg group versus 5.4 points in the 1 mg group, showing a larger improvement with the high dose.
This double-blind trial randomized 233 adults with treatment-resistant depression to a single 25 mg, 10 mg, or 1 mg dose with psychological support.
At week 3, the average Montgomery-Asberg depression score dropped by about 12.0 points in the 25 mg group...
In the same trial, 37% of the 25 mg group met response at week 3 versus 18% in the 1 mg control.
The trial defined response as a large drop in the clinician-rated depression score at week 3.
Response occurred in 37% of participants in the 25 mg group compared with 18% in the 1 mg control group, indicating higher short-term response for the high dose.
The trial defined response as a large drop in the clinician-rated depression score at week 3.
Response occurred in 37% of participants in the 25 mg group compared with 18% in the 1 mg control group, indicating higher short-term response for the high dose.
The trial reported remission at week 3 in 29% of the 25 mg group versus 8% in the 1 mg control.
Remission was defined as a low clinician-rated depression score at week 3.
The study reported remission in 29% of the 25 mg group compared with 8% of the 1 mg control group, indicating more complete symptom relief in the high-dose group.
Remission was defined as a low clinician-rated depression score at week 3.
The study reported remission in 29% of the 25 mg group compared with 8% of the 1 mg control group, indicating more complete symptom relief in the high-dose group.
A 20-patient open-label follow-up study reported that 9 participants met response and 4 met remission at week 5 after two psilocybin sessions.
In this open-label study, 20 treatment-resistant patients received two psilocybin sessions (10 mg and 25 mg) with psychological support.
At week 5, 9 participants met response criteria and 4 met remission criteria, indicating meaningful improvement for a substantial subset of patients.
In this open-label study, 20 treatment-resistant patients received two psilocybin sessions (10 mg and 25 mg) with psychological support.
At week 5, 9 participants met response criteria and 4 met remission criteria, indicating meaningful improvement for a...
In the same study of 19 completers, the average self-rated depression score fell by about 9.2 points at 5 weeks after treatment.
The six-month follow-up tracked changes on the self-rated Quick Inventory of Depressive Symptomatology.
Among 19 completers, the average score dropped by about 9.2 points at 5 weeks after treatment, showing a sizable short-term reduction in symptoms.
The six-month follow-up tracked changes on the self-rated Quick Inventory of Depressive Symptomatology.
Among 19 completers, the average score dropped by about 9.2 points at 5 weeks after treatment, showing a sizable short-term reduction in symptoms.
A 12-patient open-label feasibility study reported mean self-rated depression score reductions of 11.8 points at 1 week and 9.2 points at 3 months after the high dose.
This feasibility study gave 12 patients two doses of psilocybin (10 mg and 25 mg) with psychological support and followed them for 3 months.
The Quick Inventory of Depressive Symptomatology, a self-rated depression score, dropped by about 11.8 points at 1 week and 9.2 points at 3 months after the high dose, indicating sustained symptom relief in this small cohort.
This feasibility study gave 12 patients two doses of psilocybin (10 mg and 25 mg) with psychological support and followed them for 3 months.
The Quick Inventory of Depressive Symptomatology, a self-rated depression score, dropped by about 11.8 points at 1...
An open-label study of 19 treatment-resistant patients on selective serotonin reuptake inhibitor antidepressants found the mean Montgomery-Asberg score fell by 14.9 points at week 3, and 42% met response/remission.
This open-label study evaluated a single 25 mg psilocybin dose given with psychological support while patients continued selective serotonin reuptake inhibitor antidepressant medication.
The average Montgomery-Asberg depression score dropped by 14.9 points at week 3, and 42% of participants met response and remission criteria at that time point.
This open-label study evaluated a single 25 mg psilocybin dose given with psychological support while patients continued selective serotonin reuptake inhibitor antidepressant medication.
The average Montgomery-Asberg depression score dropped by 14.9 points...
A 7-patient pilot trial reported a mean self-rated depression score reduction of 7.14 points at the 3-week primary endpoint, with 3 of 7 reaching response and remission.
This open-label pilot trial tested a two-dose psilocybin protocol with psychotherapeutic support for treatment-resistant depression.
At the 3-week primary endpoint, the average self-rated depression score fell by 7.14 points and 3 of 7 participants met response and remission criteria.
This open-label pilot trial tested a two-dose psilocybin protocol with psychotherapeutic support for treatment-resistant depression.
At the 3-week primary endpoint, the average self-rated depression score fell by 7.14 points and 3 of 7 participants met...